Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy.
نویسندگان
چکیده
The results of recent clinical trials for the management of limited-stage Hodgkin lymphoma have led to considerable debate, especially regarding the role of radiation therapy. This review highlights those recent trials and provides perspectives regarding their interpretation from a radiation oncologist and a hematologist. The trial protocol is available at http://www.nejm.org/doi/suppl/10.1056/NEJMoa1111961/suppl_file/nejmoa1111961_protocol.pdf.
منابع مشابه
CLINICAL FEATURES AND TREATMENT OUTCOME IN 26 CASES WITH Ki-l (CD30) POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA
In order to present the clinical features and outcome of patients with Ki-l positive lymphoma and also the role of treatment modalities in this type of malignant disease, twenty-six patients with peripheral lymphadenopathy and a biopsyproven diagnosis ofKi-l positive lymphoma referring to the Radiation Oncology Department during a seven year period were treated with chemotherapy and radioth...
متن کاملPoint/counterpoint: is there a role for radiotherapy in the treatment of primary CNS lymphoma?
Primary central nervous system lymphoma (PCNSL) is a relatively rare form of extra-nodal non-Hodgkin’s lymphoma that accounts for approximately 4% of primary central nervous system tumors. Treatment with high-dose methotrexate-based chemotherapeutic regimens have resulted in response rates of 60-70% or higher and long-term survival in 15-30% of patients. – 4 While PCNSL is sensitive to radiatio...
متن کاملDevelopment of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...
متن کاملConstruction and cloning of a recombinant expression vector containing human Cd20 Gene for antibody therapy in Non-Hodgkin Lymphoma
ABSTRACT Introduction: Non-Hodgkin lymphoma (NHL) is a cancer that starts in lymphocytes. The main treatment for NHL is chemotherapy and radiation. Today immunotherapy is a promising therapeutic approach in the treatment of a variety cancers which is high specific unlike previous methods. Antibodies do not penetrate effectively into tumore tissues because of their large size. Whe...
متن کاملTreatment of Newly Diagnosed and Relapsed Hodgkin Lymphoma in Children
Hodgkin lymphoma (HL) accounts for about 10% of all childhood cancers. Five-year survival rates with modern therapies are now approaching >90-95% as a consequence of its significant sensitivity to both chemotherapy and radiation. The current challenge is to determine how much therapy is needed to improve survival and how to adapt treatment to the patient to prevent these long term toxicities. T...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Blood
دوره 120 23 شماره
صفحات -
تاریخ انتشار 2012